Mobocertinib: First Approval

Area of Science:

• Oncology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (EGFRex20ins) historically has limited treatment options.
• EGFRex20ins mutations are rare but confer resistance to existing EGFR tyrosine kinase inhibitors (TKIs).
• Targeted therapies are crucial for improving outcomes in specific NSCLC subtypes.

Purpose of the Study:

• To summarize the development milestones of mobocertinib.
• To highlight the accelerated US approval of mobocertinib for EGFRex20ins-positive NSCLC.
• To provide an overview of mobocertinib's efficacy in a specific patient population.

Main Methods:

• Review of clinical trial data for mobocertinib.
• Analysis of efficacy in patients with EGFRex20ins-positive NSCLC.
• Summary of regulatory milestones, including US accelerated approval.

Main Results:

• Mobocertinib demonstrated efficacy in a phase I/II trial for EGFRex20ins-positive NSCLC.
• Accelerated approval was granted in the USA based on these findings.
• The drug is under review for marketing approval in other regions like the EU and China.

Conclusions:

• Mobocertinib represents a significant advancement as a first-in-class TKI for EGFRex20ins-positive NSCLC.
• The accelerated approval marks a key milestone in making this targeted therapy available to patients.
• Further development and regulatory reviews are ongoing globally.